Novel Medications for Opiate Detoxification - 4
Primary Purpose
Opioid-Related Disorders, Substance-Related Disorders
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Clonidine
Sponsored by
About this trial
This is an interventional treatment trial for Opioid-Related Disorders focused on measuring Opioid-Related Disorders
Eligibility Criteria
Please contact site for information.
Sites / Locations
- VA Connecticut Healthcare System
Outcomes
Primary Outcome Measures
Withdrawal severity
Secondary Outcome Measures
Full Information
NCT ID
NCT00000279
First Posted
September 20, 1999
Last Updated
June 17, 2020
Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System
1. Study Identification
Unique Protocol Identification Number
NCT00000279
Brief Title
Novel Medications for Opiate Detoxification - 4
Official Title
Novel Medications for Opiate Detoxification
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
September 1994 (undefined)
Primary Completion Date
August 1999 (Actual)
Study Completion Date
August 1999 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate novel medications for opiate detoxification.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders, Substance-Related Disorders
Keywords
Opioid-Related Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Enrollment
0 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Clonidine
Primary Outcome Measure Information:
Title
Withdrawal severity
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas R Kosten, M.D.
Organizational Affiliation
VA Connecticut Healthcare System
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Connecticut Healthcare System
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
12. IPD Sharing Statement
Citations:
Citation
AM J Drug & Alc. Abuse 21(4): 453-467, 1995; Neuropsychopharm 13(4): 323-333, 1995; Neuropsychopharm 14(3): 187-193, 1996; J Pharma & Experimental Therapeutics 276(3): 1128-1135, 1996.
Results Reference
background
Learn more about this trial
Novel Medications for Opiate Detoxification - 4
We'll reach out to this number within 24 hrs